

Title (en)

CONTROLLED RELEASE FORMULATION COMPRISING GNRH-II ANALOGS FOR THE TREATMENT OF OR PROTECTION AGAINST DISORDERS OF BONE GROWTH

Title (de)

FORMULIERUNG MIT KONTROLLEERTER FREISETZUNG ENTHALTEND GNRH-II ANALOGA ZUR BEHANDLUNG ODER VORBEUGUNG VON KNOCHENWACHSTUMSKRANKHEITEN

Title (fr)

FORMULE A LIBERATION PROLONGEE COMPRENANT DES ANALOGUES DE LA GONADOLIBERINE-II POUR LE TRAITEMENT OU LA PREVENTION DE MALADIES DE LA CROISSANCE OSSEUSE

Publication

EP 1140133 A1 20011010 (EN)

Application

EP 99958357 A 19991202

Priority

- GB 9904045 W 19991202
- GB 9826662 A 19981203

Abstract (en)

[origin: WO0032218A1] A pharmaceutical formulation for the controlled release of a therapeutic peptide or a salt thereof, which peptide has the sequence pyroGlu-His-Trp-Ser-Xaa<1>-Gly-Xaa<2>-Xaa<3>-Pro-Gly-NH₂ wherein Xaa<1> is His or Tyr, Xaa<2> is Trp or Leu, and Xaa<3> is Tyr or Arg, provided that when Xaa<1> is Tyr and Xaa<2> is Leu, then Xaa<3> is not Arg, and which formulation further comprises a pharmaceutically acceptable biodegradable polymer. The formulation can be used for treating bone and prostate disorders.

IPC 1-7

A61K 38/09; A61K 47/34; A61P 19/08; A61P 35/00

IPC 8 full level

A61K 9/16 (2006.01); **A61K 38/00** (2006.01); **A61K 38/09** (2006.01); **A61K 47/34** (2006.01); **A61K 9/50** (2006.01); **A61P 3/10** (2006.01); **A61P 13/08** (2006.01); **A61P 19/00** (2006.01); **A61P 19/10** (2006.01); **A61P 35/00** (2006.01); **C07K 7/23** (2006.01); **C07K 14/59** (2006.01)

CPC (source: EP KR)

A61K 9/0002 (2013.01 - KR); **A61K 9/1647** (2013.01 - EP KR); **A61K 38/09** (2013.01 - EP KR); **A61P 3/10** (2018.01 - EP); **A61P 13/08** (2018.01 - EP); **A61P 19/00** (2018.01 - EP); **A61P 19/08** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **C07K 7/23** (2013.01 - EP KR)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0032218 A1 20000608; AU 1573200 A 20000619; AU 770676 B2 20040226; BR 9915943 A 20010821; CA 2353798 A1 20000608; CN 1332635 A 20020123; CZ 20011893 A3 20020515; EE 200100293 A 20020815; EP 1140133 A1 20011010; GB 2344287 A 20000607; GB 9826662 D0 19990127; HR P20010421 A2 20020630; HU P0104943 A2 20020629; HU P0104943 A3 20020828; IL 143496 A0 20020421; JP 2002531411 A 20020924; KR 20010089538 A 20011006; MX PA01005543 A 20030714; NO 20012636 D0 20010529; NO 20012636 L 20010712; NZ 511984 A 20021126; PL 348575 A1 20020603; RU 2233170 C2 20040727; SK 7552001 A3 20020205; TR 200102273 T 20011221; ZA 200104530 B 20020604

DOCDB simple family (application)

GB 9904045 W 19991202; AU 1573200 A 19991202; BR 9915943 A 19991202; CA 2353798 A 19991202; CN 99815183 A 19991202; CZ 20011893 A 19991202; EE P200100293 A 19991202; EP 99958357 A 19991202; GB 9826662 A 19981203; HR P20010421 A 20010601; HU P0104943 A 19991202; IL 14349699 A 19991202; JP 2000584909 A 19991202; KR 20017006883 A 20010601; MX PA01005543 A 19991202; NO 20012636 A 20010529; NZ 51198499 A 19991202; PL 34857599 A 19991202; RU 2001118040 A 19991202; SK 7552001 A 19991202; TR 200102273 T 19991202; ZA 200104530 A 20010601